CD274 and non-small cell lung carcinoma: In the phase II, JASPER trial, 38 patients affected by advanced NSCLC were divided in two cohorts (cohort 1: PD-L1 ≥50%; cohort 2: PD-L1=1-49%) and received first-line treatment with pembrolizumab plus niraparib.